VBI Vaccines Inc.

NASDAQ:VBIV   3:59:59 PM EDT
2.97
-0.01 (-0.34%)
Products

VBI Vaccines Announces Initial Positive Phase 1 Data For Its EVLP Vaccine Candidate Against Covid-19

Published: 06/29/2021 11:49 GMT
VBI Vaccines Inc. (VBIV) - Vbi Vaccines Announces Initial Positive Phase 1 Data for Its Evlp Vaccine Candidate Against Covid-19.
Vbi Vaccines Inc - After Two Doses, Vbi-2902a Induced Neutralization Titers in 100% of Participants.
Vbi Vaccines Inc - After Two Doses, Peak Antibody Binding Gmt Was 1:4,047.
Vbi Vaccines Inc - Study Also Supports Assessment of a One-dose Booster Regimen in Seropositive Individuals.
Vbi Vaccines Inc - Initiation of Next Phase of Ongoing Adaptive Phase 1/2 Study Expected in Q3 2021.
Vbi Vaccines Inc - Vbi-2902a Was Well-tolerated With No Safety Signals Observed.
Vbi Vaccines Inc - After Two Doses, Vbi-2902a Also Induced Antibody Binding Titers in 100% of Participants.